Laupheim, Germany, April 23, 2007 - Rentschler Biotechnologie GmbH, a full-service biopharmaceutical contract manufacturing organization (CMO) with over 30 years of experience, announced the opening of a US-based sales office in New Providence, New Jersey. Through the local representation, Rentschler intends to expand its sales activities and improve the support for its North American clients. The manufacturing and fill and finish are carried out in Rentschler´s facilities in Laupheim, Germany, in accordance with international GxP standards.


Rentschler is currently enlarging the capacities of its technological and operative plants thus allowing the production of material for supplying both clinical studies and the market. This is an important prerequisite for long-term cooperation with international clients.
Dr. Nikolaus F. Rentschler, CEO at Rentschler Biotechnologie, makes the following comment regarding the step: "We have completed a number of successful projects with clients in the United States. With the US sales office we want to further develop our North American business."


By setting up additional fermenter suites, the Rentschler Group has strengthened its biotechnology business of custom manufacturing services from cell line development to large-scale cGMP production, registration of drugs and fill & finish.



About Rentschler Biotechnologie -
Rentschler Biotechnologie GmbH is part of the Rentschler Group and is based in Laupheim, Germany. As an international full-service contract manufacturer with a highly skilled staff of 300, Rentschler Biotechnologie has more than 30 years of experience in development, production and approval of biopharmaceuticals in compliance with international GxP standards. Regulatory affairs and fill and finish also are part of the service spectrum of the enterprise. As one of the pioneers in the development and production of biopharmaceuticals, Rentschler was the first company in the world to gain market authorization for an interferon-containing drug. In 2006 Rentschler announced an investment program of €50 million for the expansion of the production systems. The first new systems will go into operation mid-2007.



For more information about Rentschler:
Dr. Wieland Wolf
Dr. Rentschler Holding GmbH & Co. KG
Mittelstraße 18
88471 Laupheim
Phone: +49 (0)7392-701-0
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


Media contact:
Friederike Braun
Rentschler Biotechnologie GmbH
Erwin-Rentschler-Straße 21
88471 Laupheim
Phone: +49 (0)7392 701-555
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.